Trial Profile
A randomised, non-comparative, multicentre, phase II, parallel-group trial of ZD1839 (Iressa) [gefitinib] in combination with 5 fluorouracil, leucovorin [folinic acid] and cpt-11 (irinotecan) in patients with metastatic colorectal cancer.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2011
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 26 Jan 2011 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 17 Jul 2007 Status changed from in progress to completed.
- 15 Dec 2005 New trial record.